Selecta Biosciences (SELB) Downgraded to Strong Sell at ValuEngine

Selecta Biosciences (NASDAQ:SELB) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.

Several other equities research analysts also recently issued reports on the company. Canaccord Genuity reiterated a “buy” rating and issued a $30.00 price objective on shares of Selecta Biosciences in a report on Thursday, January 18th. Zacks Investment Research downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Finally, UBS Group downgraded Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $23.50.

Selecta Biosciences (NASDAQ:SELB) traded down $0.25 during mid-day trading on Friday, hitting $8.76. The company had a trading volume of 220,022 shares, compared to its average volume of 281,479. The company has a debt-to-equity ratio of 0.32, a current ratio of 9.48 and a quick ratio of 9.48. The stock has a market cap of $195.67, a P/E ratio of -2.83 and a beta of -5.56. Selecta Biosciences has a 52-week low of $8.40 and a 52-week high of $24.02.

Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $0.22. Selecta Biosciences had a negative return on equity of 100.06% and a negative net margin of 1,918.59%. sell-side analysts expect that Selecta Biosciences will post -2.25 EPS for the current fiscal year.

In related news, Director Timothy A. Springer purchased 57,598 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were bought at an average price of $9.27 per share, for a total transaction of $533,933.46. Following the acquisition, the director now directly owns 461,349 shares in the company, valued at $4,276,705.23. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Earl Sands purchased 7,500 shares of the business’s stock in a transaction on Friday, November 17th. The shares were bought at an average price of $10.26 per share, for a total transaction of $76,950.00. Following the acquisition, the insider now owns 7,500 shares in the company, valued at $76,950. The disclosure for this purchase can be found here. Insiders purchased a total of 90,098 shares of company stock worth $843,933 in the last quarter. Company insiders own 41.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of SELB. Schwab Charles Investment Management Inc. purchased a new stake in Selecta Biosciences during the 2nd quarter worth about $392,000. Rhumbline Advisers purchased a new stake in Selecta Biosciences during the 2nd quarter worth about $239,000. Bank of New York Mellon Corp increased its holdings in Selecta Biosciences by 119.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 32,400 shares of the company’s stock worth $644,000 after purchasing an additional 17,664 shares during the period. Teachers Advisors LLC boosted its position in shares of Selecta Biosciences by 294.2% during the 2nd quarter. Teachers Advisors LLC now owns 21,292 shares of the company’s stock worth $423,000 after acquiring an additional 15,890 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Selecta Biosciences by 714.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 41,807 shares of the company’s stock worth $830,000 after acquiring an additional 36,674 shares in the last quarter. Institutional investors own 54.81% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/04/selecta-biosciences-selb-downgraded-to-strong-sell-at-valuengine.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply